Know Cancer

or
forgot password

Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L) in Patients With Advanced Malignancies


Phase 1
13 Years
N/A
Open (Enrolling)
Both
Advanced Cancers

Thank you

Trial Information

Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L) in Patients With Advanced Malignancies


The Study Drugs:

Curcumin is the active ingredient in the spice, turmeric. It is a natural anti-inflammatory
compound and has shown anti-tumor activity. Surface-controlled water dispersible curcumin is
designed to be better absorbed by the body than regular curcumin.

Study Groups:

The first group of participants will receive the lowest dose level. Each new group will
usually receive a higher dose than the group before it, if no intolerable side effects were
seen. Each group will have 3-6 participants. This will continue until the highest tolerable
dose of curcumin is found. Up to 6 dose levels of curcumin will be tested. Once the highest
tolerable dose of each arm is found, up to 14 extra participants will be enrolled for extra
safety testing.

In some cases, extra participants may be enrolled at dose levels shown to be safe for extra
safety and/or PK and PD testing.

You will be assigned to a dose level based on when you join this study.

The dose of the study drug that you receive may be lowered if you have any intolerable side
effects. If you are tolerating the treatment, your study drug dose may be increased after
the first cycle to the highest dose level shown to be safe.

Study Drug Administration:

Each study "cycle" is 28 days long.

You will take 1 dose of curcumin on Day 1 of Cycle 1. Starting on Day 2 of Cycle 1, you will
begin taking curcumin 2 times each day.

Curcumin is a liquid that comes in a bottle, and you will take it by mouth on an empty
stomach with a full glass of water (8 ounces). If you are not tolerating the doses and your
doctor thinks it is needed, you may take curcumin in divided doses several times a day with
food.

Study Visits:

Before your first dose of study drug and during Week 2 of Cycle 2, you will complete a
questionnaire about your quality of life. It should take about 5-10 minutes to complete.

Every week of Cycle 1 and then as often as the doctor thinks it is needed, blood (about 2
teaspoons) will be drawn for routine tests.

Before you begin each cycle:

- Your medical history will be recorded.

- You will have a physical exam, including measurement of your weight and vital signs.

- Your performance status will be recorded.

- You will be asked about any side effects you may be having.

At the end of Cycle 2 and then every 2-3 cycles:

- You will have a chest x-ray, CT, MRI, and/or PET scan to check the status of the
disease. If the study doctor thinks it is needed, these scan may be performed more
often. You also may have extra types of scans not listed in this consent form.

- If the doctor thinks it is needed, blood (about 1 teaspoon) will be drawn to measure
tumor markers.

PK Testing:

Blood (about ½ teaspoon each time) will be drawn for PK testing at the following times:

- On Day 1 of Cycle 1, blood will be drawn before the dose and then 6 more times over the
next 6 hours after the dose.

- On Day 2 of Cycle 1, blood will be drawn 1 time.

Length of Study:

You may remain on study for as long as the study doctor thinks it is in your best interest.
You will be taken off study early if the disease gets worse or you experience intolerable
side effects.

Your participation on the study will be over once you have completed the end-of-study visit.

End-of-Study Visit:

Within 30 days after your last dose of the study drug(s), you will have an end-of-study
visit. At this visit the following tests and procedures will be performed:

- Your medical history will be recorded.

- You will have a physical exam, including measurement of your weight and vital signs.

- Your performance status will be recorded.

- Blood (about 2 teaspoons) will be drawn for routine tests.

- You will be asked about any side effects you may be having.

- If the study doctor thinks it is needed, you will have a chest x-ray, CT, MRI, and/or
PET scan to check the status of the disease. If the study doctor thinks it is needed,
you may also have extra types of scans.

- If the study doctor thinks it is needed, blood (about 1 teaspoon) will be drawn to
measure tumor markers.

This is an investigational study. Curcumin is a commercially available substance, which is
commonly used as a food additive. Curcumin is not FDA approved for any usage. At this time,
curcumin is only being used in research.

Up to 72 patients will take part in this study. All will be enrolled at MD Anderson.


Inclusion Criteria:



1. Patients must have an advanced malignancy that has either failed one or more prior
therapies, or for which there is no established standard of care therapy that
improves survival by at least 3 months. If standard therapies are available, the
informed consent states that patients are forgoing approved therapies proven to
prolong life or the time that the patient is alive without growth of their cancer.

2. Patients must have an ECOG performance status of 3 or better (0-3).

3. Patients must have normal organ and marrow function as defined below: Absolute
neutrophil count > 1,000 /uL Platelets > 50,000 /uL Total bilirubin limit of normal (ULN) (except patients with Gilbert's syndrome, who must have a total
bilirubin < 3.0 mg/dL) and ALT clearance >/= 40 ml/min

4. Patients must be able to understand and be willing to sign an IRB-approved written
informed consent document.

5. Women of child-bearing potential (women who are not postmenopausal for at least one
year or are not surgically sterile) and men must agree to use adequate contraception
(e.g., barrier device) prior to study entry, for the duration of study participation,
and for 30 days after the last dose.

6. Patients may receive palliative radiation therapy immediately before or during the
treatment if the radiation therapy is not delivered to the sole target lesions.

7. Men and women aged >/= 18 years. However, patients who are 13 years or older will be
eligible after consultation with their pediatric attending.

Exclusion Criteria:

1. Uncontrolled intercurrent illness including, but not limited to, symptomatic
congestive heart failure (NYHA Class III or IV), unstable angina pectoris, active
bleeding that requires hospitalization, or psychiatric illness/social situations that
would limit compliance with study requirements.

2. Subject that has not recovered from major surgical procedure, open biopsy, or
significant traumatic injury (i.e. subject still needs additional medical care for
these issues).

3. History of gastric or duodenal ulcers, or hyperacidity syndromes.

4. History of allergic reactions to the study drug or its analogs.

5. Patient that has received any treatment for tumor specific control within 3 weeks of
the start of study drug with investigational drugs and cytotoxic agents, or within 2
weeks of cytotoxic agent given weekly, or within 6 weeks of nitrosoureas or mitomycin
C, or within 5 half-lives of biological targeted agents with half-lives and
pharmacodynamic effects lasting less than 5 days (that includes, but is not limited
to, erlotinib, sorafenib, sunitinib, bortezomib, and other similar agents).

6. Currently taking therapeutic doses of anticoagulants such as warfarin or antiplatelet
agents (any prophylaxis agents are acceptable).

7. INR > 1.5

8. Biliary obstruction or cholelithiasis.

9. Inability to take oral medication (PEG tube is acceptable).

10. Pregnant or breastfeeding women.

11. Concurrent enrollment on another therapeutic research study.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum Tolerated Dose (MTD)

Outcome Description:

Evaluation of measurable tumor: the same imaging technique used during the initial evaluation or more sophisticated studies will be performed once every 8 weeks or sooner if clinically indicated.

Outcome Time Frame:

8 weeks

Safety Issue:

Yes

Principal Investigator

David S. Hong, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

UT MD Anderson Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

2010-0276

NCT ID:

NCT01201694

Start Date:

October 2011

Completion Date:

Related Keywords:

  • Advanced Cancers
  • Advanced malignancies
  • Surface-controlled water soluble curcumin
  • Turmeric
  • Dietary supplements
  • Neoplasms

Name

Location

UT MD Anderson Cancer CenterHouston, Texas  77030